SHPH SHUTTLE PHARMACEUTICALS HOLDINGS INC Management Changes 8-K Filing 2025 - Management Restructuring On March 31, 2025, Shuttle Pharmaceuticals amended Dr. Anatoly Dritschilo's employment agreement, appointing him as Chief Scientific Officer and Chairman, while Christopher Cooper becomes interim CEO, with Dritschilo's annual compensation set at $274,000 and a focus on clinical trials for Ropidoxuridine.Get access to all SEC 8-K filings of the SHUTTLE PHARMACEUTICALS HOLDINGS INC